ResearcherDuke UniversityNo recent work listed

Lingling Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8907-6495; OpenAlex author ID A5091220064. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper

Papers 3

Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hbpd.2021.08.012 ↗
Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk. Co-author DOI 10.1002/cam4.3603 ↗
Associations of novel variants in PIK3C3, INSR and MAP3K4 of the ATM pathway genes with pancreatic cancer risk. Co-author PMID 32775006 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qingyi Wei · 2 shared papers, 2020 · strength 0.26
- Paper Associations of novel variants in PIK3C3, INSR and MAP3K4 of the ATM pathway genes with pancreatic cancer risk. PMID 32775006 ↗
- Paper Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk. DOI 10.1002/cam4.3603 ↗
Wei Li · 2 shared papers, 2020 · strength 0.26
- Paper Associations of novel variants in PIK3C3, INSR and MAP3K4 of the ATM pathway genes with pancreatic cancer risk. PMID 32775006 ↗
- Paper Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk. DOI 10.1002/cam4.3603 ↗
Jiuwei Cui · 1 shared paper, 2022 · strength 0.20
- Paper Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1016/j.hbpd.2021.08.012 ↗
Ri-Lan Bai · 1 shared paper, 2022 · strength 0.20
- Paper Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma. DOI 10.1016/j.hbpd.2021.08.012 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.